Vishal is the Founder of AUM Biosciences, the Award-winning oncology focused biotech company. He also serves as the Chairman of AUM’s Board of Directors. Under Vishal’s leadership, AUM has become a clinical stage company, and developed a portfolio of transformative cancer medicines within 12 months of inception and awarded the 2019 Asia-Pacific Biotech Entrepreneurial Company of The Year by world renowned Frost and Sullivan. A pharmacist by training, Vishal is an experienced senior management with extensive experience in commercial deal structuring over a USD$3 Billion including JV, Licensing, M&A and Long-term strategic partnerships. His strong scientific background in Medicinal Chemistry comes from breast cancer research in Aromatase inhibitors in the UK. He also brings a strong track record of working on a global virtual pharma model: A $145M PE deal with Eisai in the including 3 major blockbusters, such as Lenvima (Peak sales ~$3B/Y), Eribulin (Peak Sales ~$500M/Y), and ONTAK (Peak sales ~$100M/Y). He is also a Key Opinion Leader with the Korean Health Industry Development Institute which is part of the Ministry of Health and Welfare initiative in Korea. He has graduated as a pharmacist from University of Mumbai and a Master degree in Pharmaceutical sciences from Kingston University.